Cagrilintide
Also known as: AM833, Long-acting amylin analog
Overview
Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk. Amylin is a 37-amino acid peptide co-secreted with insulin from pancreatic beta cells that suppresses postprandial glucagon, slows gastric emptying, and promotes satiety. Cagrilintide's extended half-life allows once-weekly subcutaneous dosing. When combined with semaglutide (as CagriSema), the dual amylin/GLP-1 mechanism produced up to 25.2% weight loss in Phase II trials, with Phase III data anticipated in 2025–2026.
Mechanism of Action
Cagrilintide binds amylin receptors (AMY1, AMY2, AMY3 — complexes of calcitonin receptor with receptor activity-modifying proteins RAMP1-3) in the area postrema and nucleus accumbens, activating cAMP-mediated signaling. This suppresses postprandial glucagon secretion, delays gastric emptying to reduce postprandial glycemic excursions, and activates hypothalamic satiety circuits via POMC neurons. The amylin mechanism is complementary and additive to GLP-1 receptor agonism, explaining the superior weight loss of the CagriSema combination.
Potential Benefits
- Sustained appetite suppression via amylin receptor activation
- Postprandial glucagon suppression
- Gastric emptying delay reducing postprandial glucose excursions
- Significant weight loss as monotherapy (10–15%)
- Superior weight loss in combination with semaglutide (up to 25.2% in Phase II)
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | 0.16 mg weekly titrating upward |
| Intermediate | 1.2 mg weekly |
| Advanced | 2.4 mg weekly (Phase II dose) |
| Cycle Duration | Chronic use for weight management (trial protocol) |
Novo Nordisk amylin analog. Typically co-administered with semaglutide ('CagriSema').
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Subcutaneous Injection High
Once-weekly SC injection. As part of CagriSema fixed-dose combination at 2.4 mg. Also studied as monotherapy (2.4 mg/week in Phase 2). Dose escalation protocol over ~16 weeks.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Cagrilintide:
CagriSema (Cagrilintide + Semaglutide)
Phase III combination therapy for obesity — ~15-20% weight loss in Phase II. Co-formulated once-weekly injection.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Refrigerate at 2-8°C after reconstitution. Do not freeze reconstituted solution. |
|---|
Typical vial sizes: 5-10 mg. Add bac water slowly down the side of the vial, swirl gently — do not shake. Use insulin syringe for precise dosing.
Need exact syringe measurements?
Amino Acid Sequence
Modified 37 AA amylin sequence with fatty acid acylation for half-life extension
Side Effects & Safety
- Nausea and vomiting (class effect)
- Injection site reactions
- Diarrhea
- Decreased appetite (intended but can be excessive)
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Drug Interactions
- Oral Medications (general):
Pharmacokinetics
| Half-Life | ~7 days (acylated amylin analog with long-chain fatty acid for albumin binding; once-weekly dosing) |
|---|---|
| Storage | Refrigerate at 2–8°C; do not freeze; protect from light; administered as part of CagriSema fixed-dose pen |
Synergistic Compounds
The following compounds have been studied alongside Cagrilintide for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA PCAC July 2026: What the BPC-157 peptide compounding review really means
FDA’s Pharmacy Compounding Advisory Committee will review seven unapproved peptides in July 2026. What that process means for BPC-157—and what it doesn’t.
FDA signals enforcement against unapproved compounded GLP-1 drugs: what it means for peptide medicine
The FDA says it will restrict GLP-1 APIs used in mass-marketed unapproved compounded drugs and crack down on advertising that calls them generic versions of branded drugs.
Sublingual compounded peptides: Quicksome claims and what the FDA’s July 2026 PCAC review could change
A press release claims needle-free, sublingual delivery for popular compounded peptides—just as the FDA's PCAC prepares a July 2026 review of seven peptides.
Pemvidutide IMPACT 48-Week MASH Data Lands At EASL 2026 Ahead Of Phase 3
Altimmune's pemvidutide hit 32.4% ELF response, 23.7% triglyceride drop, and 54.5% qFibrosis regression in 212-patient F2/F3 MASH IMPACT Phase 2b at EASL 2026.